Share this article
Share this article
LONDON, Dec. 21, 2020 /PRNewswire/ LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public Health (FOPH) Authorization for the LumiraDx SARS-CoV-2 Antigen Test, following a positive technical validation conducted by the Swiss Society for Microbiology (SSM). The test achieved 98.4-100% positive agreement and 99% negative agreement compared to RT-PCR.
The LumiraDx SARS-CoV-2 Antigen Test is to be used with the LumiraDx Platform and detects antigen nucleocapsid protein from nasal or nasopharyngeal swabs with accurate qualitative results in 12 minutes. It uses next generation microfluidic immunofluorescence technology to deliver high sensitivity.
DETALJAN VODIČ ZA GASTARBAJTERE Šta vam je sve potrebno da uđete u Srbiju, a šta da se posle VRATITE U INOSTRANSTVO? blic.rs - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blic.rs Daily Mail and Mail on Sunday newspapers.